UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Position in Catalent, Inc. (NYSE:CTLT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Catalent, Inc. (NYSE:CTLT) by 4.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,024,240 shares of the company’s stock after purchasing an additional 45,564 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.56% of Catalent worth $62,038,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Catalent by 12.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,982 shares of the company’s stock worth $2,301,000 after acquiring an additional 4,088 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in Catalent by 166.5% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company’s stock worth $83,733,000 after purchasing an additional 863,624 shares in the last quarter. BNP Paribas Financial Markets grew its position in Catalent by 9.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 267,219 shares of the company’s stock worth $16,185,000 after purchasing an additional 22,785 shares during the last quarter. Brooklyn Investment Group purchased a new stake in Catalent during the 3rd quarter worth approximately $31,000. Finally, Quantbot Technologies LP acquired a new position in Catalent during the 3rd quarter valued at approximately $7,222,000.

Catalent Stock Performance

NYSE CTLT opened at $61.45 on Tuesday. The firm has a market capitalization of $11.15 billion, a P/E ratio of -27.19, a PEG ratio of 2.43 and a beta of 1.16. The stock has a 50-day simple moving average of $59.93 and a two-hundred day simple moving average of $58.55. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. Catalent, Inc. has a fifty-two week low of $36.74 and a fifty-two week high of $61.50.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the prior year, the business posted ($0.10) earnings per share. The firm’s revenue was up 4.2% compared to the same quarter last year. On average, equities analysts forecast that Catalent, Inc. will post 0.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

CTLT has been the subject of several research reports. StockNews.com upgraded shares of Catalent from a “sell” rating to a “hold” rating in a research note on Monday. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. William Blair reissued a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Eight equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $63.40.

Insider Activity at Catalent

In related news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. The trade was a 5.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at $646,849.50. This represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock worth $305,931 in the last three months. Company insiders own 0.31% of the company’s stock.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.